Proactive's analyst-in-residence, Ryan Long, takes a detailed look at just how large the McDermitt project...
10.23 Wed 13 Nov 2019
BevCanna Enterprises Inc (CNSX:BEV) offers investors an early-stage opportunity in the emerging...
Enteq upstream (LON:NTQ) is a leading supplier of high-end systems and products for measurement...
Georgina Energy is an energy company offering investors exposure to an increasingly...
Fast-track gold projects are few and far between and projects with relatively low capital...
Shield Therapeutics (LON:STX) has reported further data from its non-inferiority AEGIS H2H study...
Gfinity (LON:GFIN) is a world leader in the fast-growing market for esports. The company...
Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in...
Itaconix (LON:ITX) has issued a trading update for the financial year to 31 December 2019. The...
Proactive Research analyst Emma Ulker discusses further positive data which has been released from Shield Therapeutics' (LON:STX) non-inferiority AEGIS H2H study. It pitted Shield's oral ferric maltol (branded as Feraccru in Europe and Accrufer in US) against intravenous ferric carboxymaltose...
